Overview

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving an hepatic arterial infusion of melphalan together with hepatic perfusion works in treating patients with unresectable liver cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Delcath Systems Inc.
Collaborator:
National Cancer Institute (NCI)
Treatments:
Melphalan